Related Experiment Videos
Thrombophilias and gynaecology
Kitty W M Bloemenkamp1, Frans M Helmerhorst, Frits R Rosendaal
1Department of Obstetrics, Gynaecology and Reproductive Medicine, Leiden University Medical Center, P.O. Box 9600, RC 2300, Leiden, The Netherlands. kwm.bloememkamp@planet.nl
Summary
Sex steroids in gynecological treatments like oral contraceptives and hormone replacement therapy increase venous thrombosis risk, especially with clotting defects. Third-generation oral contraceptives pose a higher risk than second-generation ones.
Area of Science:
- Gynecology
- Hematology
- Reproductive Medicine
Background:
- Hormonal therapies, including oral contraceptives (OCs) and hormone replacement therapy (HRT), are widely used in gynecology.
- These therapies involve exposure to sex steroids, which can influence hemostasis.
- Venous thromboembolism (VTE) is a significant risk associated with these treatments.
Purpose of the Study:
- To examine the association between sex steroid exposure in gynecological treatments and the risk of venous thrombosis.
- To investigate the synergistic effect of inherited clotting defects with OCs and HRT on VTE risk.
- To explore the potential VTE risk associated with assisted reproductive technologies.
Main Methods:
- Review of existing literature on hormonal therapies and VTE.
- Analysis of comparative risks between different generations of OCs.
- Examination of interactions between genetic thrombophilia and hormonal treatments.
- Evaluation of emerging data on VTE risk with in vitro fertilization (IVF) and ovulation induction.
Main Results:
- OCs and HRT are established risk factors for VTE, with the highest risk in the first year of use.
- Third-generation OCs are associated with a nearly twofold increased VTE risk compared to second-generation OCs.
- Inherited clotting defects (e.g., Factor V Leiden, protein deficiencies) act synergistically with OCs to elevate VTE risk.
- Emerging evidence suggests IVF and ovulation induction may also increase VTE risk, though the role of clotting defects is unclear.
Conclusions:
- Sex steroid exposure through OCs and HRT significantly elevates VTE risk, particularly in women with underlying clotting defects.
- The choice of OC generation impacts VTE risk, with newer generations posing a greater hazard.
- Further research is needed to elucidate the mechanisms and risks associated with VTE in the context of assisted reproduction.